LadRx Corp
LadRx Corp is a Delaware-based biopharmaceutical research company focused on oncology drug discovery and clinical development. Its core platform, LADR™, is designed to target chemotherapeutic drugs to solid tumors while reducing off-target toxicities, and the company also developed a companion diagnostic, ACDx™, to identify patients most likely to benefit from treatment.
Fiscal year 2024 · change from previous year
Development 2019–2024
Business
Share of revenueTargeted anti-cancer drug candidates designed to deliver chemotherapeutic payloads to solid tumors and reduce toxicity.
ACDx™ diagnostic tools intended to identify patients most likely to respond to the company’s drug candidates.
Contractual rights to receive milestone, royalty and related payments from partnered assets and license agreements.
Historical management, consulting and administrative support provided to the Centurion subsidiary structure.
Customers
LadRx does not currently operate as a commercial drug seller; its economic counterparties are primarily pharmaceutical partners, licensees, and potential strategic collaborators. In practice, value is created for oncology drug developers, clinical-stage partners, and acquirers that may license or fund the LADR platform and related assets. The company also depends on capital providers and transaction counterparties to monetize its intellectual property while it remains pre-revenue.
Companies that license LADR-based assets or related rights to advance oncology programs and commercialize them.
Biopharma collaborators that may fund trials, share development risk, or enter joint ventures around the platform.
Partners obligated to pay contingent consideration under prior license or assignment agreements.
Equity investors, lenders, or other financing sources needed to sustain operations and development work.
Strategy
The company’s strategy is to preserve and monetize the LADR platform through strategic partnerships, licensing, royalty sales, grants, or equity financing. Near term, management is focused on securing capital and/or a transaction that can fund continued development, because the business currently has no recurring revenue and remains a going-concern risk.
The company has no recurring revenue and needs external capital to continue operating.
Licensing and partnering are the main paths to value creation for a pre-commercial biotech.
Clinical progress is needed to improve partnering leverage and long-term asset value.
Geography
LadRx is headquartered in Los Angeles, California, and is incorporated in Delaware. Its historical research footprint included a discovery laboratory in Freiburg, Germany, but that lab was closed in 2019, so current operations are largely U.S.-based with international exposure mainly through intellectual property and licensing arrangements.
Risks
LadRx is a pre-revenue biotech with substantial going-concern risk, so its survival depends on successful financing or partnering. Its value is also highly dependent on clinical, regulatory, and intellectual property outcomes, while royalty and milestone monetization can be volatile and non-recurring.
The company has no recurring revenue and expects continued losses unless it secures financing or a strategic partnership.
Exposure: Corporate survival and ability to fund operations
LADR candidates are still dependent on preclinical and future clinical success, which is uncertain in oncology.
Exposure: LADR-7 to LADR-10 pipeline
Drug candidates and any derived products require FDA and other regulatory approvals before commercialization.
Exposure: Arimoclomol-related contingent payments and future product pathways
The business depends on patent protection and enforceability of its LADR technology and related rights.
Exposure: Domestic and international patent portfolio
Royalty and milestone receipts depend on partner performance and contractual triggers, which may not occur.
Exposure: License and assignment agreements
Accounting
Judgemental itemsThe company treated the XOMA royalty agreement as an in-substance sale of non-financial assets, recording proceeds in other income rather than revenue.
Impact: Affects reported revenue, other income, and operating performance comparability
Equity awards are measured using Black-Scholes and recognized over vesting periods, which can materially affect G&A expense.
Impact: Impacts operating loss and non-cash expense trends
The company must assess whether capitalized assets remain recoverable given its limited operations and uncertain commercialization path.
Impact: Could trigger write-downs and reduce asset values
Preclinical and development costs require judgment in estimating accrued liabilities and expense timing.
Impact: Affects quarterly expense recognition and liabilities
Financial statements are prepared assuming continuation despite substantial doubt, which is critical for interpretation.
Impact: Signals liquidity risk and affects valuation assumptions
Similar listed companies
Publicly listed companies with a comparable business focus.
Lantern Pharma Inc.
LTRN · Pharmaceutical Preparations
Genprex, Inc.
GNPX · Pharmaceutical Preparations
ALX Oncology Holdings Inc
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
Janux Therapeutics, Inc.
JANX · Pharmaceutical Preparations
Janux Therapeutics is a clinical-stage biopharmaceutical company developing cancer immunotherapies built on its proprietary TRACTr, TRACIr, and ARM platforms.
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Onconetix, Inc.
ONCO · Pharmaceutical Preparations
Last updated: 24/09/2026